Business
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
GMP Facility Expected to Simplify the mRNA Drug Substance Development Process; Slated to Welcome Customers in Early 2024 SAN DIEGO--(BUSINESS WIRE)-- TriLink
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"\nGMP Facility Expected to Simplify the mRNA Drug Substance Development Process; Slated to Welcome Customers in Early 2024\n\n\n SAN DIEGO--(BUSINESS WIRE)--\n\nTriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.\n\n\nTriLink has reliably delivered GMP services to its customers since the debut of its first cGMP manufacturing facility in 2015. Built to meet the need of a rapidly growing market, the new cGMP facility is expected to contribute to the development of vital mRNA therapeutics. The building has been designed for the cGMP manufacture of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.\n\n\n“The expansion of our cGMP mRNA manufacturing capabilities marks a major milestone for TriLink and our partners,” said Becky Buzzeo, Chief Commercial Officer at Maravai LifeSciences. “Drug developers will soon be able to leverage our team’s 25-plus years of industry expertise, helping to take critical therapeutics from concept to plasmid DNA through to late-phase clinical mRNA drug substance manufacturing with ease.”\n\n\nJust minutes from the company’s San Diego headquarters, the new facility boasts ISO 7 cleanrooms and increased mRNA capacity (1g to >50g per batch), with comprehensive in-house analytical services also available. “Our team took great care in building and designing our new facility– it’s truly been a labor of love,” added Rob Carpenter, Vice President of Engineering at TriLink. “In addition to having access to a state-of-the-art facility, developers will also have a direct line to our experienced team to help with process optimization, scale-up, validation, and qualification capabilities.”\n\n\nTo learn more about TriLink’s products and services, visit trilinkbiotech.com\n\n\nAbout TriLink BioTechnologies\n\n\nTriLink BioTechnologies, a Maravai LifeSciences company, is helping to realize the power and potential of mRNA. As a global leader ...